NCT04162301View on ClinicalTrials.gov

A Study of CS3002 in Subjects With Advanced Solid Tumors

PHASE1TerminatedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

December 30, 2019

Primary Completion Date

February 19, 2021

Study Completion Date

February 19, 2021

Conditions
Advanced Solid Tumor
Interventions
DRUG

CS3002

CS3002 tablet will be orally administered daily for 3 weeks followed by 1 week off treatment, defining a treatment cycle of 28 days in duration.

Trial Locations (2)

2050

Chris O'Brien Lifehouse, Camperdown

3199

Peninsula and South Eastern Haematology and Oncology Group, Heidelberg

Sponsors
All Listed Sponsors
lead

CStone Pharmaceuticals

INDUSTRY